Symbol | Exchange | Currency |
|---|
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company’s lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 207.46 | 207.79 | 197.20 | +12.18 | +6.24% | 168.62M | NASDAQ | |||
| 164.90 | 165.00 | 161.91 | +2.54 | +1.56% | 67.09M | NASDAQ | |||
| 62.03 | 62.25 | 61.87 | +0.18 | +0.29% | 14.06M | NYSE | |||
| 211.94 | 212.17 | 206.77 | +4.10 | +1.97% | 25.22M | NASDAQ | |||
| 103.73 | 103.89 | 101.04 | +2.84 | +2.81% | 35.75M | NASDAQ | |||
| 289.27 | 289.27 | 283.00 | +5.22 | +1.84% | 32.09M | NASDAQ | |||
| 40.80 | 40.83 | 40.28 | +0.42 | +1.04% | 22.83M | NYSE | |||
| 98.01 | 98.36 | 95.27 | +0.13 | +0.13% | 55.43M | NASDAQ | |||
| 103.29 | 103.49 | 101.95 | +1.29 | +1.26% | 55.70M | NASDAQ | |||
| 166.04 | 166.68 | 164.29 | +3.37 | +2.07% | 1.51M | NASDAQ | |||
| 277.77 | 278.34 | 271.05 | +3.94 | +1.44% | 42.98M | NASDAQ | |||
| 8.45 | 8.48 | 8.08 | +0.30 | +3.68% | 26.03M | NYSE | |||
| 104.00 | 104.19 | 101.44 | +2.68 | +2.65% | 27.08M | NASDAQ | |||
| 47.94 | 48.13 | 45.95 | +1.43 | +3.07% | 13.46M | NYSE | |||
| 52.02 | 52.35 | 51.39 | +0.59 | +1.15% | 20.24M | NASDAQ |